Aiwa Health Inc.

Aiwa Health Inc. focuses on providing genetic testing services to assist in diagnosing rare diseases through a convenient at-home testing model, enhancing accessibility for patients globally. Aiwa Health Inc. , known as Probably Genetic, specializes in genetic testing for rare diseases.

The company was founded by Lukas Lange, who has a background in healthcare innovation. The headquarters is located in Karlsruhe, Germany. The firm has engaged in 2 funding deals, with the most recent being a Seed round on June 18, 2019, which raised USD 0. 15 mn, contributing to a total amount raised of USD 10.

72 mn. Probably Genetic specializes in providing comprehensive genetic testing for over 4,000 rare diseases, utilizing a user-friendly at-home testing model. Their core offering includes clinical-grade genetic testing kits that are sent directly to patients, allowing for the collection of saliva or cheek swab samples in the comfort of their homes. The service is designed to facilitate the diagnosis of genetic conditions, especially in cases where traditional medical evaluations have failed to provide clear answers.

The company primarily serves patients and caregivers seeking insights into unexplained symptoms or hereditary health risks, supported by over 50 patient advocacy groups that connect users with additional resources and community support. Probably Genetic has a global reach, offering these services to clients in various international markets, thus ensuring accessibility for a diverse customer base. Probably Genetic operates a no-cost model for its genetic testing services, meaning that eligible patients incur no charges for comprehensive genetic tests or professional counseling sessions. The firm generates revenue through partnerships with healthcare providers and patient advocacy groups, which may involve collaborative initiatives aimed at enhancing awareness and facilitating testing for specific genetic conditions.

Transactions occur directly between Probably Genetic and patients, with no insurance information or financial documentation required, streamlining the process for users. The company's revenue structure is centered on its mission to provide accessible genetic testing without financial barriers, effectively targeting individuals and families facing diagnostic challenges related to rare diseases. Aiwa Health Inc. aims to expand its product offerings to include additional genetic testing panels tailored for specific rare diseases, with plans to launch these by mid-2020.

The company is also targeting expansion into the European and North American markets within the next two years. The recent Seed funding from Khosla Ventures, Oxford Angel Fund, and TenOneTen will be utilized to enhance product development and support market entry strategies.